Biocon Wins Japan Approval for Pegfilgrastim Biosimilar

Biocon Biologics, a subsidiary of Biocon Limited, has received marketing approval in Japan for its pegfilgrastim biosimilar. The product is a version of Amgen's Neulasta^®, and will be promoted, sold, and distributed exclusively in Japan by Sandoz K.K.

The approval strengthens Biocon's biosimilar portfolio in the Japanese market and supports its strategy of widening global patient access to cost-effective biologic medicines. The move reinforces Biocon's positioning as a significant player in the international biosimilars arena.

As a leading developer and manufacturer of biological medicines, Biocon Limited operates globally through its wholly owned subsidiary Biocon Biologics Ltd. The company develops and manufactures biological medicines targeting oncology and other chronic conditions, aiming to expand access to high-quality, affordable therapies in key regulated markets such as Japan.